Skip to content
Peptigraph home
Shop Peptides50% off*

PT-141 Benefits: Claims vs What Studies Show

Benefits people claim for PT-141, set against what published studies measured, and where no study exists.

Medical review pendingMelanocortin agonistUpdated
Strongest evidence
Human RCT
Human / animal studies
12 / 0
in our evidence file (PubMed search, 2 Oct 2026)
FDA status
Approved for HSDD (Vyleesi)

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

PT-141 claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
Erectile dysfunctionHuman RCT evidence, 4 of 49 / 0Desire and distress across subgroups; Patient-reported experience; Sexual desire (FSFI-desire domain)Evidence for erectile dysfunction

Strongest study per claim: Erectile dysfunction, Journal of women's health 2022, PMID 35230162.

What the studies measured

PT-141 outcomes in published studies
OutcomeResultStudy typeSource
Desire and distress across subgroupsBenefit on desire and distress was seen across age, weight and BMI subgroups.Human RCTn = 1202Journal of women's health 2022, PMID 35230162
Patient-reported experienceExit surveys and interviews: bremelanotide users described more desire, arousal and better sexual activity quality.Human RCTn = 242Journal of women's health 2021, PMID 33538638
Sexual desire (FSFI-desire domain)Desire domain score rose more than placebo: 0.30 (study 301), 0.42 (study 302), 0.35 integrated, all P<.001.Human RCTn = 1267Obstetrics and gynecology 2019, PMID 31599840
Distress related to low desireDistress fell more than placebo: -0.37, -0.29 and -0.33 integrated.Human RCTn = 1267Obstetrics and gynecology 2019, PMID 31599840
Responder ratesAt 1.75 mg, responder rates beat placebo on all 7 endpoints (P ≤ .03).Human RCTThe journal of sexual medicine 2019, PMID 31277966
Satisfying sexual events+0.7 versus +0.2 satisfying sexual events per month (p = 0.0180).Human RCTn = 327Women's health 2016, PMID 27181790
Positive clinical response in sildenafil non-responders51 (33.5%) of the bremelanotide group had positive clinical results versus 13 (8.5%) on placebo (p = 0.03).Human RCTn = 342The Journal of urology 2008, PMID 18206919
Sexual desireMore women reported moderate or high desire after bremelanotide than placebo (P = 0.0114).Human RCTn = 18The journal of sexual medicine 2006, PMID 16839319
Vaginal vasocongestionNo significant change in vaginal vasocongestion versus placebo.Human RCTn = 18The journal of sexual medicine 2006, PMID 16839319
Erectile response (RigiScan)Erectile response was statistically significant versus placebo at both 4 mg and 6 mg in men with inadequate response to Viagra.Human RCTInternational journal of impotence research 2004, PMID 14999221
Erectile response (RigiScan)Erectile response beat placebo at doses above 7 mg; first erection began in about 30 minutes.Human RCTInternational journal of impotence research 2004, PMID 14963471
Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab]”: 114 results. PubMed search on 2 Oct 2026 for “(bremelanotide[tiab] OR "PT-141"[tiab]) AND randomized controlled trial[pt]”: 14 results. PubMed search on 2 Oct 2026 for “(bremelanotide[tiab] OR "PT-141"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab])”: 7 results. PubMed search on 2 Oct 2026 for “(bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab]) AND (erectile[tiab] OR men[tiab])”: 20 results.

Claimed: it raises sexual desire (women)

In two phase 3 randomized, placebo-controlled trials of premenopausal women with hypoactive sexual desire disorder, the desire score rose more than with placebo, and distress about low desire fell more.[3]

An earlier phase 2b dose-finding trial in premenopausal women reported more satisfying sexual events per month at the pooled higher doses than on placebo.[5]

Exit surveys and interviews from the phase 3 trials relay what participants said, not a new measurement: women on the active drug described more desire, physical arousal and better sexual activity.[2]

Claimed: it improves arousal

In an 18-woman crossover study of a single intranasal dose, genital blood-flow measurement showed no significant change against placebo, even though self-reported desire was higher.[7]

Claimed: it helps erections in men

In a 342-man trial of men with erectile dysfunction who had not responded to sildenafil, positive clinical results were seen in 51 men on intranasal bremelanotide against 13 on placebo.[6]

A small crossover study in men with erectile dysfunction measured erections by RigiScan after subcutaneous dosing and found a statistically significant response against placebo.[8]

What the approved product's label rules out

The only FDA-approved bremelanotide product is limited to premenopausal women with acquired, generalized low desire, and its label states it is not indicated in postmenopausal women or in men.[14]

The same label also says the product is not for enhancing sexual performance.[14]

Claims with no trial behind them here

PubMed on 2 October 2026 returned 14 records for bremelanotide or PT-141 limited to randomized controlled trials, so a claim not tied to one of those trials, such as tanning or general well-being, has no study cited on this site.

Calculated from evidence file web/src/data/evidence/pt-141.json; query (bremelanotide[tiab] OR "PT-141"[tiab]) AND randomized controlled trial[pt]; date 2026-10-02; records 14. Formula: randomized-trial records returned = 14

More on PT-141

DosageSide effectsResultsHow it works

Common questions

Is PT-141 proven to work?

Only for the approved indication, where trials were placebo-controlled; the men's erectile dysfunction results come from intranasal and subcutaneous studies and never led to an approved use.

Calculated from approved indication premenopausal women, acquired generalized HSDD; men ed indication approved no; source web/src/data/evidence/pt-141.json notes. Formula: approved indications for men = 0

What does PT-141 do?

In people it was studied for sexual function: the approved product's label calls it a melanocortin receptor agonist for low sexual desire in premenopausal women, and its label says how it works in that condition is unknown.[14]

More on PT-141

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.How it worksTarget, mechanism and how long it acts, from the label or studies.Nasal sprayStudies that gave PT-141 as nasal spray, and what is approved.

Sources

  1. 1Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.Journal of women's health (2002) · 2022PMID 35230162Accessed 2 Oct 2026
  2. 2The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.Journal of women's health (2002) · 2021PMID 33538638Accessed 2 Oct 2026
  3. 3Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstetrics and gynecology · 2019PMID 31599840Accessed 2 Oct 2026
  4. 4Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.The journal of sexual medicine · 2019PMID 31277966Accessed 2 Oct 2026
  5. 5Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.Women's health (London, England) · 2016PMID 27181790Accessed 2 Oct 2026
  6. 6Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.The Journal of urology · 2008PMID 18206919Accessed 2 Oct 2026
  7. 7An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.The journal of sexual medicine · 2006PMID 16839319Accessed 2 Oct 2026
  8. 8Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.International journal of impotence research · 2004PMID 14999221Accessed 2 Oct 2026
  9. 9Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.International journal of impotence research · 2004PMID 14963471Accessed 2 Oct 2026
  10. 10PubMed search: bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab] (114 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab]) AND randomized controlled trial[pt] (14 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab]) AND (erectile[tiab] OR men[tiab]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14VYLEESI prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.